Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy

Ping Jin, Ena Wang, Maurizio Provenzano, David Stroncek, Francesco M. Marincola

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Treatment with human recombinant interleukin-2 (rIL-2) can successfully eradicate advanced cancer in humans; however, its utilization is limited by the unpredictability of its effectiveness and the excessive toxicity often associated with its use. The mechanisms responsible for immune-mediated tumor regression and those associated with limiting toxicity have not yet been sorted out. Thus, this review critically addresses what has been done in the past to understand this biologically and practically important question and discusses future strategies to enhance the understanding of this interesting model of immune-mediated tumor rejection. In particular, the first aim of this review is to discuss what is known about the mechanism(s) responsible for tumor rejection; the second aim is to review the relationship between the toxicity induced by rIL-2 treatment and its effectiveness; the third aim is to summarize novel insights into the possible mechanism of rIL-2 activity in vivo using high-throughput strategies aimed at the global assessment in real-time of events associated with rIL-2 therapy in humans. This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs.

Original languageEnglish
Pages (from-to)437-448
Number of pages12
JournalCritical Reviews in Immunology
Volume27
Issue number5
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Transcriptome
Interleukin-2
Neoplasms
Biological Factors
Therapeutics
In Vitro Techniques

Keywords

  • Functional genomics
  • Immunotherapy
  • Interleukin-2
  • Melanoma
  • Microarray
  • Renal cell cancer

ASJC Scopus subject areas

  • Immunology

Cite this

Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. / Jin, Ping; Wang, Ena; Provenzano, Maurizio; Stroncek, David; Marincola, Francesco M.

In: Critical Reviews in Immunology, Vol. 27, No. 5, 2007, p. 437-448.

Research output: Contribution to journalReview article

Jin, Ping ; Wang, Ena ; Provenzano, Maurizio ; Stroncek, David ; Marincola, Francesco M. / Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. In: Critical Reviews in Immunology. 2007 ; Vol. 27, No. 5. pp. 437-448.
@article{d1b86a2b4abf4f76a59dce4387a75706,
title = "Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy",
abstract = "Treatment with human recombinant interleukin-2 (rIL-2) can successfully eradicate advanced cancer in humans; however, its utilization is limited by the unpredictability of its effectiveness and the excessive toxicity often associated with its use. The mechanisms responsible for immune-mediated tumor regression and those associated with limiting toxicity have not yet been sorted out. Thus, this review critically addresses what has been done in the past to understand this biologically and practically important question and discusses future strategies to enhance the understanding of this interesting model of immune-mediated tumor rejection. In particular, the first aim of this review is to discuss what is known about the mechanism(s) responsible for tumor rejection; the second aim is to review the relationship between the toxicity induced by rIL-2 treatment and its effectiveness; the third aim is to summarize novel insights into the possible mechanism of rIL-2 activity in vivo using high-throughput strategies aimed at the global assessment in real-time of events associated with rIL-2 therapy in humans. This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs.",
keywords = "Functional genomics, Immunotherapy, Interleukin-2, Melanoma, Microarray, Renal cell cancer",
author = "Ping Jin and Ena Wang and Maurizio Provenzano and David Stroncek and Marincola, {Francesco M.}",
year = "2007",
language = "English",
volume = "27",
pages = "437--448",
journal = "Critical Reviews in Immunology",
issn = "1040-8401",
publisher = "Begell House Inc.",
number = "5",

}

TY - JOUR

T1 - Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy

AU - Jin, Ping

AU - Wang, Ena

AU - Provenzano, Maurizio

AU - Stroncek, David

AU - Marincola, Francesco M.

PY - 2007

Y1 - 2007

N2 - Treatment with human recombinant interleukin-2 (rIL-2) can successfully eradicate advanced cancer in humans; however, its utilization is limited by the unpredictability of its effectiveness and the excessive toxicity often associated with its use. The mechanisms responsible for immune-mediated tumor regression and those associated with limiting toxicity have not yet been sorted out. Thus, this review critically addresses what has been done in the past to understand this biologically and practically important question and discusses future strategies to enhance the understanding of this interesting model of immune-mediated tumor rejection. In particular, the first aim of this review is to discuss what is known about the mechanism(s) responsible for tumor rejection; the second aim is to review the relationship between the toxicity induced by rIL-2 treatment and its effectiveness; the third aim is to summarize novel insights into the possible mechanism of rIL-2 activity in vivo using high-throughput strategies aimed at the global assessment in real-time of events associated with rIL-2 therapy in humans. This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs.

AB - Treatment with human recombinant interleukin-2 (rIL-2) can successfully eradicate advanced cancer in humans; however, its utilization is limited by the unpredictability of its effectiveness and the excessive toxicity often associated with its use. The mechanisms responsible for immune-mediated tumor regression and those associated with limiting toxicity have not yet been sorted out. Thus, this review critically addresses what has been done in the past to understand this biologically and practically important question and discusses future strategies to enhance the understanding of this interesting model of immune-mediated tumor rejection. In particular, the first aim of this review is to discuss what is known about the mechanism(s) responsible for tumor rejection; the second aim is to review the relationship between the toxicity induced by rIL-2 treatment and its effectiveness; the third aim is to summarize novel insights into the possible mechanism of rIL-2 activity in vivo using high-throughput strategies aimed at the global assessment in real-time of events associated with rIL-2 therapy in humans. This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs.

KW - Functional genomics

KW - Immunotherapy

KW - Interleukin-2

KW - Melanoma

KW - Microarray

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=38049047954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049047954&partnerID=8YFLogxK

M3 - Review article

VL - 27

SP - 437

EP - 448

JO - Critical Reviews in Immunology

JF - Critical Reviews in Immunology

SN - 1040-8401

IS - 5

ER -